The most commonly reported side effects of sibeprenlimab include pain, pain in extremity, and dysgeusia, based on 2 FDA adverse event reports from 2020 to 2024.
Percentages show how often each reaction appears relative to total reports for sibeprenlimab.
These are voluntary reports and do not establish that sibeprenlimab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside sibeprenlimab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
50.0% of sibeprenlimab adverse event reports involve female patients and 0.0% involve male patients. The largest age group is adult at 100%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Sibeprenlimab is sold under the brand name Voyxact.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.